Biota, Inc.

18 articles about Biota, Inc.

• Biota Advances "Biology as a Data Business"

  9/1/2020

  DEPLOYING ENVIRONMENTAL GENOMICS PLATFORM TO BROADER INDUSTRIAL BIOTECHNOLOGY MARKET

• Biota, Inc. Receives $4.2 Million R&D Tax Credit

  11/7/2012

• Biota, Inc., Nabi Biopharmaceuticals Amend Merger Terms; $54 Million Transaction Down to $27 Million

  9/18/2012

• Biota, Inc. Announces Inavir Achieves Primary Endpoint in Phase III Prevention Study

  8/22/2012

• Biota, Inc. Announces Royalties from Inavir(R) and Relenza(TM) for Q4 and F2011

  8/1/2011

• Biota, Inc. Announces Preliminary Phase III Prophylaxis Trial Results for CS-8959

  6/27/2011

• Biota, Inc. Obtains US$2.9M National Institutes of Health (NIH) Grant for the Development of Novel Antibacterial

  6/10/2011

• Biota, Inc. Announces Relenza Royalty for March 2011 Quarter

  4/28/2011

• Biota, Inc. Announces Relenza Royalty for March 2011 Quarter

  4/28/2011

• Biota, Inc. Announces Relenza September Quarter Royalty of $2.1 Million from GlaxoSmithKline

  10/22/2010

• Biota, Inc.'s HCV Research Agreement With Boehringer Ingelheim Corporation Concludes

  4/20/2010

• Biota, Inc. Completes Asset Purchase From Maxthera, Inc.

  3/4/2010

• Biota, Inc. Announces Half Year Net Profit of $33.5 Million

  2/17/2010

• Biota, Inc.'s Flu Drug Succeeds in Late-Stage Asia Trial

  8/10/2009

• Biota, Inc. Announces Half Year Net Profit of AU$5.5 Million

  2/22/2008

• Biota, Inc. Raises Relenza Claim to US$485 - US$605 Million

  7/31/2007

• Biota, Inc. Awarded Up To US $8.5 Million To Develop LANI/FLUNET Compounds

  8/8/2006

• Biota Holdings Limited Raises $31 Million

  10/27/2005